Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651437 | 0.93 | NPY2R (0.77) | NPY2R | |
| SCHEMBL13884190 | 0.91 | NPY2R (0.56) | NPY2R | |
| SCHEMBL3655097 | 0.90 | NPY2R (0.55) | NPY2R | |
| SCHEMBL13883808 | 0.82 | NPY2R (0.62) | NPY2RKDM4E | |
| SCHEMBL5081025 | 0.81 | NPY2R (0.79) | NPY2R | |
| SCHEMBL3654216 | 0.80 | NPY2R (0.60) | NPY2R | |
| SCHEMBL5084675 | 0.80 | NPY2R (1.00) | NPY2R | |
| SCHEMBL3659790 | 0.80 | NPY2R (0.79) | NPY2R | |
| SCHEMBL13873619 | 0.79 | NPY2R (0.76) | NPY2R | |
| SCHEMBL8736279 | 0.76 | NPY2R (0.54) | NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205561-A2 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050197-A2 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050197-A2 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099199-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090099199-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090099199-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099199-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLC10A6, SLCO1B1 | NPY2R 2590/4885KDM4E 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.